284 related articles for article (PubMed ID: 32627120)
1. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
3. Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.
Mujugira A; Karungi B; Mugisha J; Nakyanzi A; Nampewo O; Naddunga F; Kamusiime B; Nsubuga R; Nyanzi KR; Muwonge TR; Wyatt MA; Ware NC; Gandhi M; Haberer JE
J Int AIDS Soc; 2024 May; 27(5):e26255. PubMed ID: 38695107
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention.
Spinelli M; Gandhi M
Expert Rev Mol Diagn; 2024 Mar; 24(3):169-175. PubMed ID: 38353417
[TBL] [Abstract][Full Text] [Related]
5. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
Spinelli MA; Haberer JE; Chai PR; Castillo-Mancilla J; Anderson PL; Gandhi M
Curr HIV/AIDS Rep; 2020 Aug; 17(4):301-314. PubMed ID: 32424549
[TBL] [Abstract][Full Text] [Related]
6. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.
Gandhi M; Wang G; King R; Rodrigues WC; Vincent M; Glidden DV; Cressey TR; Bacchetti P; Spinelli MA; Okochi H; Siriprakaisil O; Klinbuayaem V; Mugo NR; Ngure K; Drain PK; Baeten JM
AIDS; 2020 Feb; 34(2):255-260. PubMed ID: 31634188
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.
Gandhi M; Bacchetti P; Spinelli MA; Okochi H; Baeten JM; Siriprakaisil O; Klinbuayaem V; Rodrigues WC; Wang G; Vincent M; Cressey TR; Drain PK
J Acquir Immune Defic Syndr; 2019 May; 81(1):72-77. PubMed ID: 30664078
[TBL] [Abstract][Full Text] [Related]
9. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
[TBL] [Abstract][Full Text] [Related]
10. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
Jin X; Wang H; Li H; Chu Z; Zhang J; Hu Q; Lv W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Ding H; Geng W; Jiang Y; Shang H; Xu J;
BMC Public Health; 2020 Jul; 20(1):1160. PubMed ID: 32709230
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP".
Mayer KH; Safren SA; Elsesser SA; Psaros C; Tinsley JP; Marzinke M; Clarke W; Hendrix C; Wade Taylor S; Haberer J; Mimiaga MJ
AIDS Behav; 2017 May; 21(5):1350-1360. PubMed ID: 27848089
[TBL] [Abstract][Full Text] [Related]
12. Combination adherence strategy to support HIV antiretroviral therapy and pre-exposure prophylaxis adherence during pregnancy and breastfeeding: protocol for a pair of pilot randomised trials.
Saidi F; Mutale W; Freeborn K; Rosenberg NE; Graybill LA; Maman S; Amico KR; Mollan KR; Phanga T; Milala B; Hill LM; Gottwalt AM; Phiri S; Kalua T; Chi BH
BMJ Open; 2021 Jun; 11(6):e046032. PubMed ID: 34193491
[TBL] [Abstract][Full Text] [Related]
13. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
[TBL] [Abstract][Full Text] [Related]
14. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.
Elliott T; Sanders EJ; Doherty M; Ndung'u T; Cohen M; Patel P; Cairns G; Rutstein SE; Ananworanich J; Brown C; Fidler S
J Int AIDS Soc; 2019 Dec; 22(12):e25419. PubMed ID: 31850686
[TBL] [Abstract][Full Text] [Related]
15. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
Baeten JM; Heffron R; Kidoguchi L; Mugo NR; Katabira E; Bukusi EA; Asiimwe S; Haberer JE; Morton J; Ngure K; Bulya N; Odoyo J; Tindimwebwa E; Hendrix C; Marzinke MA; Ware NC; Wyatt MA; Morrison S; Haugen H; Mujugira A; Donnell D; Celum C;
PLoS Med; 2016 Aug; 13(8):e1002099. PubMed ID: 27552090
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis.
Moorthy GS; Lalley-Chareczko L; Koenig HC; Zuppa AF
Curr Clin Pharmacol; 2020; 15(2):102-104. PubMed ID: 31713497
[TBL] [Abstract][Full Text] [Related]
18. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
Bardon AR; Dorward J; Sookrajh Y; Sayed F; Quame-Amaglo J; Pillay C; Feutz E; Ngobese H; Simoni JM; Sharma M; Cressey TR; Gandhi M; Lessells R; Moodley P; Naicker N; Naidoo K; Thomas K; Celum C; Abdool Karim S; Garrett N; Drain PK
BMJ Open; 2021 Oct; 11(10):e050116. PubMed ID: 34610939
[TBL] [Abstract][Full Text] [Related]
19. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
20. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
